Development of mycobacterial growth inhibition assays for the early evaluation and gating of novel TB vaccine candidates
<p>Tuberculosis poses a serious global health threat, with an estimated 9 million new cases and 1.5 million deaths annually. The current vaccine, BCG, is inadequate but development of an effective alternative is severely hampered by the lack of an immune correlate of protection. Candidate vacc...
Autore principale: | Tanner, R |
---|---|
Altri autori: | McShane, H |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
2015
|
Soggetti: |
Documenti analoghi
Documenti analoghi
-
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
di: Pepponi, I, et al.
Pubblicazione: (2017) -
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
di: Rachel Tanner, et al.
Pubblicazione: (2020-01-01) -
In vitro Mycobacterial Growth Inhibition in South Korean Adults With Latent TB Infection
di: Hyejon Lee, et al.
Pubblicazione: (2019-04-01) -
Mycobacterial glycoproteins: a novel subset of vaccine candidates
di: Antonio eFacciuolo, et al.
Pubblicazione: (2014-09-01) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
di: Tanner, R, et al.
Pubblicazione: (2021)